Holen Sie sich die Stockscreener-App
2.12
1.40%
-0.03
Schlusskurs vom Vortag:
$2.15
Offen:
$2.19
24-Stunden-Volumen:
18,295
Relative Volume:
0.28
Marktkapitalisierung:
$5.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.11M
KGV:
-0.1978
EPS:
-10.7181
Netto-Cashflow:
$-13.60M
1W Leistung:
-10.55%
1M Leistung:
-22.91%
6M Leistung:
-45.64%
1J Leistung:
-64.96%
1-Tages-Spanne:
$2.12
$2.245
1-Wochen-Bereich:
$2.01
$2.435
52-Wochen-Spanne:
$1.76
$14.24
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Firmenname
Processa Pharmaceuticals Inc
Sektor
Branche
Telefon
443-776-3133
Adresse
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
2.12 | 5.83M | 0 | -14.11M | -13.60M | -10.72 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-25 | Eingeleitet | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Aktie (PCSA) Neueste Nachrichten
Shareholders to vote on Processa (NASDAQ: PCSA) equity plan and pay - Stock Titan
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Processa Pharmaceuticals Inc (PCSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Processa Pharmaceuticals Inc (PCSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Processa Pharmaceuticals Inc - TradingKey
Processa Pharmaceuticals Inc (PCSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Processa Pharmaceuticals Inc (PCSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Processa Pharmaceuticals Inc (PCSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Processa Pharmaceuticals Inc (PCSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Processa Pharmaceuticals Inc (PCSA) Institutional Confidence - TradingKey
Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
Processa Pharmaceuticals CFO Russell Skibsted buys $5,891 in stock By Investing.com - Investing.com Canada
Processa Pharmaceuticals CEO George Ng buys $5,472 in stock By Investing.com - Investing.com Canada
Processa Pharmaceuticals CEO George Ng buys $5,472 in stock - Investing.com
Processa Pharmaceuticals chief business officer Lin buys $4,064 stock - Investing.com UK
Processa Pharma president of R&D David Young buys $4,588 in stock - Investing.com Canada
Insider David Young adds 2,067 Processa (PCSA) shares at $2.22 - Stock Titan
Processa Pharmaceuticals (PCSA) CFO buys 2,654 shares in open market - Stock Titan
Processa Pharmaceuticals (PCSA) CEO adds 2,465 shares in open-market buy - Stock Titan
Processa Pharmaceuticals (PCSA) officer adds 1,831 shares in open-market buy - Stock Titan
Processa Pharmaceuticals (PCSA) CAO buys 2,118 shares at $2.22 in open market - Stock Titan
PCSA Q4 2025 Earnings: EPS Misses Estimates by 67.97% as Pre-Revenue Biotech Faces HeadwindsWeak Earnings Momentum - newsline.com
Processa Pharmaceuticals, Inc. - MLQ.ai
PCSA Stock Chart | PROCESSA PHARMACEUTICALS INC (NASDAQ:PCSA) - ChartMill
PCSA Stock Price, Quote & Chart | PROCESSA PHARMACEUTICALS INC (NASDAQ:PCSA) - ChartMill
Processa Pharmaceuticals CAO Wendy Guy buys $4,700 in stock By Investing.com - Investing.com India
Processa Pharmaceuticals CAO Wendy Guy buys $4,700 in stock - Investing.com
Processa Pharmaceuticals’ pres. David Young buys $4,590 in stock By Investing.com - Investing.com India
Processa Pharmaceuticals chief business and strategy officer buys $4,065 in stock - Investing.com Nigeria
Processa Pharmaceuticals’ pres. David Young buys $4,590 in stock - Investing.com
Processa Pharmaceuticals (PCSA) R&D chief buys 1,786 shares at $2.57 - Stock Titan
Processa Pharmaceuticals (PCSA) CFO adds 2,292 shares in open-market buy - Stock Titan
Processa (NASDAQ: PCSA) CEO adds 2,129 shares in open-market buy - Stock Titan
Processa (NASDAQ: PCSA) officer adds to stake with share purchase - Stock Titan
Processa (PCSA) CAO Wendy Guy adds 1,829 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Young David - Moomoo
Processa Pharmaceuticals (PCSA) Edges Lower as Biotech Volatility PersistsThe Legal Advocate - The Legal Advocate
Processa Pharmaceuticals (PCSA) Surges 5.75% as Shares Test Key Resistance LevelVolume Spike Alerts - The Legal Advocate
PCSA Q4 2025 Earnings: EPS Misses Estimates Amid Pipeline DevelopmentEarnings Decline Risk - The Legal Advocate
Processa Pharmaceuticals Inc. (PCSA) Q4 2025 Earnings: EPS Misses Estimates as Biotech Focuses on Clinical PipelineConsensus Miss Rate - newsline.com
Processa Pharmaceuticals Inc. (PCSA) Q4 2025 Earnings: Wider-Than-Expected Loss as Clinical Pipeline ProgressesGuidance Downgrade Alert - The Legal Advocate
Processa Pharmaceuticals CAO Wendy Guy buys $4,701 in stock By Investing.com - Investing.com India
Processa Pharmaceuticals CEO George Ng buys $5,473 in stock By Investing.com - Investing.com India
Processa Pharmaceuticals president David Young buys $4,588 in shares - Investing.com India
Sian Bigora, Processa CDO, buys $5,341 in stock - Investing.com UK
Processa Pharmaceuticals president David Young buys $4,588 in shares By Investing.com - Investing.com Australia
Processa Pharmaceuticals CAO Wendy Guy buys $4,701 in stock - Investing.com
Processa Pharmaceuticals CEO George Ng buys $5,473 in stock - Investing.com
Finanzdaten der Processa Pharmaceuticals Inc-Aktie (PCSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):